Jan Gunnar Hatlebakk

List of Publications by Year
in descending order

47	1,418	331670 21	345221 36
papers	citations	h-index	g-index

48	48	48	1197
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Longâ€term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2022, 34, e14200.	3.0	25
2	Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology and Motility, 2022, , e14353.	3.0	7
3	The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scandinavian Journal of Gastroenterology, 2022, 57, 1036-1045.	1.5	7
4	Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology, 2022, 163, 982-994.e14.	1.3	35
5	Changes in fecal shortâ€chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2021, 33, e13983.	3.0	37
6	Ultrasound imaging for assessing functions of the GI tract. Physiological Measurement, 2021, 42, 024002.	2.1	8
7	Gastroparesis Symptoms Associated with Intestinal Hypomotility: An Explorative Study Using Wireless Motility Capsule. Clinical and Experimental Gastroenterology, 2021, Volume 14, 133-144.	2.3	3
8	Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology, 2021, 27, 2219-2237.	3.3	22
9	Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterology and Motility, 2021, 33, e14157.	3.0	29
10	Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides, 2020, 79, 101973.	2.2	30
11	Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut, 2020, 69, 859-867.	12.1	291
12	Study protocol of the Bergen brain-gut-microbiota-axis study. Medicine (United States), 2020, 99, e21950.	1.0	11
13	Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients, 2020, 12, 1991.	4.1	9
14	The Effect of Supplementation with Low Doses of a Cod Protein Hydrolysate on Satiety Hormones and Inflammatory Biomarkers in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients, 2020, 12, 3421.	4.1	4
15	Density of Musashiâ€'1â€'positive stem cells in the stomach of patients with irritable bowel syndrome. Molecular Medicine Reports, 2020, 22, 3135-3140.	2.4	1
16	Letter: faecal microbiota transplantation for irritable bowel syndromeâ€"which improvements are required?. Alimentary Pharmacology and Therapeutics, 2020, 52, 1752-1753.	3.7	1
17	Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients, 2019, 11, 1824.	4.1	86
18	Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients, 2019, 11, 1635.	4.1	10

#	Article	IF	Citations
19	Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients, 2019, 11, 1415.	4.1	39
20	Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports, 2019, 20, 787-794.	2.4	14
21	Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology, 2019, 54, 690-699.	1.5	29
22	Gastric Emptying of Low- and High-Caloric Liquid Meals Measured Using Ultrasonography in Healthy Volunteers. Ultrasound International Open, 2019, 05, E27-E33.	0.6	16
23	Pathophysiology of idiopathic gastroparesis and implications for therapy. Scandinavian Journal of Gastroenterology, 2019, 54, 8-17.	1.5	19
24	Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food and Nutrition Research, 2019, 63, .	2.6	6
25	The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS ONE, 2018, 13, e0194904.	2.5	59
26	Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial. Journal of Nutritional Science, 2018, 7, e33.	1.9	28
27	Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2017, 52, 691-697.	1.5	16
28	Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports, 2017, 15, 2106-2112.	2.4	8
29	The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2017, 11, 139-148.	3.0	24
30	Abnormalities in endocrine and immune cells are correlated in dextran-sulfate-sodium-induced colitis in rats. Molecular Medicine Reports, 2017, 15, 12-20.	2.4	11
31	Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2017, 52, 1331-1339.	1.5	10
32	Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports, 2016, 14, 4967-4974.	2.4	17
33	Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports, 2016, 4, 651-656.	2.0	26
34	Peroral endoscopic pyloromyotomy for primary pyloric stenosis. Endoscopy, 2015, 47, E637-E638.	1.8	5
35	The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal, 2015, 14, 92.	3.4	53
36	Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides, 2015, 67, 12-19.	2.4	18

#	Article	IF	Citations
37	Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology, 2015, 21, 9577.	3.3	24
38	Is irritable bowel syndrome an organic disorder?. World Journal of Gastroenterology, 2014, 20, 384.	3.3	79
39	Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine, 2014, 34, 967-974.	4.0	17
40	Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2014, 2014, 1-8.	1.5	28
41	Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study. Scandinavian Journal of Pain, 2014, 5, 85-90.	1.3	7
42	Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Review of Gastroenterology and Hepatology, 2014, 8, 435-443.	3.0	36
43	Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology, 2014, 20, 2383.	3.3	35
44	The role of peptide YY in gastrointestinal diseases and disorders. International Journal of Molecular Medicine, 2013, 31, 275-282.	4.0	50
45	Irritable bowel syndrome the role of gut neuroendocrine peptides. Frontiers in Bioscience - Elite, 2012, E4, 2683-2700.	1.8	55
46	ULTRASOUND IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. Advanced Series in Biomechanics, 2005, , 461-490.	0.1	1
47	Pharmacokinetic Optimisation in the Treatment of Gastro-Oesophageal Reflux Disease. Clinical Pharmacokinetics, 1996, 31, 386-406.	3.5	71